Skip to main content
. 2015 Oct 14;6(34):36245–36259. doi: 10.18632/oncotarget.5768

Figure 9. Enhanced NK cell degranulation upon interaction with axitinib-treated A-498 RCC cells is ROS-dependent.

Figure 9

A-498 RCC cells were treated with axitinib 12.5 μM for 72 h with or without pretreatment with NAC 10 mM for 1 h, and then incubated with freshly isolated human peripheral blood NK cells from two different healthy donors at 1:1 ratio for 2 h. Results are expressed as percentage of CD107a+ NK cells.